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Abstract
We report that engineered Cas9 variants with improved specificity—eCas9-1.1 and Cas9-HF1—are often poorly active in
human cells, when complexed with single guide RNAs (sgRNAs) with a mismatch at the 5’ terminus, relative to target
DNA sequences. Because the nucleotide at the 5’ end of sgRNAs, expressed under the control of the commonly-used U6
promoter, is fixed to a guanine, these attenuated Cas9 variants are not useful at many target sites. By using sgRNAs with
matched 5’ nucleotides, produced by linking them to a self-cleaving ribozyme, the editing activity of Cas9 variants can be
rescued without sacrificing high specificity.
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Background
Clustered, regularly interspaced, short palindromic repeats
(CRISPR) – CRISPR-associated (Cas) RNA-guided endo-
nucleases, derived from adaptive immune systems in
bacteria and archaea, have been repurposed for targeted
genome editing in various cells and organisms [1–4].
These nucleases cleave chromosomal DNA in a targeted
manner, producing site-specific DNA double-strand
breaks (DSBs), the repair of which via non-homologous
end-joining (NHEJ) induces small insertions or deletions
(indels) at target sites. Unfortunately, off-target DNA
cleavage at sites that are highly homologous to on-target
sites can lead to mutations at undesired genomic loci [5,
6] and to chromosomal rearrangements such as transloca-
tions and inversions [6–8]. Both S. pyogenes Cas9 [9, 10]
and single guide RNAS (sgRNAs) [6, 11, 12] have been
modified to minimize or eliminate these off-target effects.
In particular, two groups have independently presented
engineered Cas9 variants, termed enhanced Cas9-1.1
(eCas9-1.1) [9] and Cas9 high-fidelity variant 1 (Cas9-
HF1) [10], with minimal or no detectable off-target effects
in human cells. These high-specificity Cas9 variants
contain alanine substitutions to weaken non-specific ionic
interactions between the Cas9 protein and the non-target
or target DNA strand.
Here, we show that these attenuated Cas9 variants are
poorly active at sites with a mismatched 5’ nucleotide rela-
tive to their sgRNA sequences in human cells. By using
sgRNAs with matched 5’ nucleotides relative to their target
DNA sequences, generated by self-cleaving ribozyme
fusion, the cleavage activity of the Cas9 variants was rescued
in human cells without sacrificing their high specificities.
Results
We hypothesized that the attenuated Cas9 variants might
be poorly active at sites with a mismatch at the 5’ terminus.
Because the U6 promoter, which is commonly used to ex-
press sgRNAs in eukaryotic cells, requires a guanosine (G)
nucleotide to initiate transcription, sgRNAs typically con-
tain a G nucleotide at the 5’ terminus. Three out of four
DNA target sites will contain a mismatch at this position
and thus might be poorly edited in cells by attenuated Cas9
variants in complex with gX19 sgRNAs (Fig. 1a), where “g”
or “G” is a mismatched or matched guanosine, respectively.
Note that high-specificity Cas9 variants have been previ-
ously tested at target sites with a G nucleotide at the 5’ end
of the target DNA strand using GX19 sgRNAs [9, 10].
Before testing this hypothesis, we compared expres-
sion levels of Cas9 variants in human cells and found
that the two variants, especially Cas9-HF1, were poorly
expressed in HeLa cells (Fig. 1b). We noted that our
plasmid encoding wild-type Cas9 (termed Cas9-WT
hereinafter) and the two plasmids encoding Cas9 vari-
ants [9, 10] contained different promoters, tags, and
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codon sequences [4, 6]. We performed site-directed mu-
tagenesis in our Cas9-WT plasmid to obtain constructs
encoding the two high-specificity Cas9 variants. Western
blot analysis showed that all three proteins were highly
expressed in HeLa cells (Fig. 1b). Consistent with this
result, eCas9-1.1 and Cas9-HF1 expressed using the new
constructs induced indels at the EMX1 site with efficien-
cies comparable to Cas9-WT (Fig. 1c). Based on these
results, we used the newly cloned constructs to express
eCas9-1.1 and Cas9-HF1 throughout this study.
Reduced editing activity of high-fidelity Cas9 variants at
target sites with a mismatched 5’ nucleotide
To test whether the attenuated Cas9 variants are poorly
active at sites with a mismatch at the 5’ terminus, we
compared editing activities of eCas9-1.1 and Cas9-HF1
with those of Cas9-WT at 26 sites whose 5’ terminal nu-
cleotides are not guanosine in HeLa cells using gX19
sgRNAs: the sites with a 5’ cytosine (C) were termed CX19
(seven sites); those with a 5’ thymine (T), TX19 (ten sites);
and those with a 5’ adenosine (A), AX19 (nine sites) (Fig. 2a
and b, Additional file 1: Table S1 and Table S2). As
expected, Cas9-WT was not sensitive to the mismatch at
the 5’ end, inducing indels at high frequencies (64 ± 5% at
CX19 sites; 65 ± 5% at TX19 sites; 80 ± 2% at AX19 sites, on
average). eCas9-1.1 showed much lower indel frequencies
at CX19 sites (36 ± 10%) and TX19 sites (24 ± 10%), a 1.8-
fold or 2.7-fold reduction in average indel frequencies at
CX19 or TX19 sites, respectively. Cas9-HF1 was least active
among the three Cas9 nucleases, with average indel fre-
quencies of 9.0 ± 3% at CX19 sites and 20 ± 10% at TX19
sites, which corresponds to 7.1-fold and 3.2-fold reductions,
a
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Fig. 1 High-specificity Cas9 variants with attenuated cleavage activity. a Schematics of Cas9-WT, engineered Cas9 variants, and sgRNA variants.
Locations of the alanine substitutions introduced in Cas9-WT to create eCas9-1.1 or Cas9-HF1 are shown with blue or red asterisks, respectively.
Red triangles indicate cleavage positions. GX19 sgRNA starts with a G matched to its protospacer (blue line). gX19 sgRNA has a mismatched G at its
5’-end. gX20 sgRNA includes an extra guanine at its 5’ terminus. The protospacer-adjacent motif (PAM) is shown by a red line labeled NGG. H, not
G (A or C or T); D, not C (A or G or T). b, c Western blot (b) and indel frequencies at the EMX1 site (c) of HeLa cells co-transfected with plasmids
encoding Cas9-WT or variants and EMX1-specific sgRNA. Cas9 variants were expressed by new plasmids used in this study or by old plasmids used
in previous studies. Error bars, s.e.m of two or three biological replicates
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respectively. At AX19 target sites, however, both eCas9-1.1
and Cas9-HF1 showed indel efficiencies (81 ± 3% and 79 ±
3%) comparable to that of Cas9-WT (80 ± 2%), suggesting
that a G:T mismatch at the 5’ terminus may still form a
wobble base pair. These results are in line with a previous
report showing Cas9-HF1 activities with three and one
gX19 sgRNAs at CX19 and AX19 sites, respectively [10].
We chose six CX19 or TX19 target sites at which the
two Cas9 variants were poorly active and tested gX20
sgRNAs with an extra guanosine at the 5’ terminus
rather than gX19 sgRNAs (Fig. 2c). Note that gX20
sgRNAs, unlike gX19 sgRNAs, have matched nucleotides
at the 5’ end. Use of gX20 sgRNAs enhanced the activity
of Cas9 variants at AAVS1-01 and HBB-02 sites but re-
duced the activity at the other four sites, compared to
gX19 sgRNAs. We also noted that Cas9-WT was more
efficient with gX19 sgRNAs than with gX20 sgRNAs at all
six sites. These results show that gX20 sgRNAs cannot
rescue the genome editing activities of high-specificity
Cas9 variants. These Cas9 variants in combination with
gX19 and gX20 sgRNAs also showed lower indel
frequencies than Cas9-WT in HEK293T, another human
cell line (Additional file 1: Figure S1).
Rescue of high-specificity Cas9 variants using Hammerhead
ribozyme-linked sgRNAs
To expand the utility of high-fidelity Cas9 variants, we
produced sgRNAs with matched 5’ nucleotides by using
a self-cleaving ribozyme. Thus, each sgRNA was fused to
a Hammerhead (HH) ribozyme at its 5’-end [13], which
generates mature 20-nucleotide (X20) sgRNAs after self-
cleavage (Fig. 3a). HH ribozyme-fused sgRNAs with
matched 5’ nucleotides (termed HH-X20) or the mis-
matched 5’ guanosine nucleotide (termed HH-gX19)
were tested in combination with Cas9-WT and high-
fidelity Cas9 variants in HeLa cells (Fig. 3b). Use of HH-
X20 sgRNAs rescued the activity of the two Cas9 variants
at all six target sites. Thus, indel frequencies obtained
with eCas9-1.1 (64 ± 6%) and Cas9-HF1 (55 ± 7%) using
HH-X20 sgRNAs were comparable to those obtained
with Cas9-WT (69 ± 5% or 70 ± 3%) using HH-X20
sgRNAs or HH-gX19 sgRNAs, respectively (Fig. 3c and
a
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Fig. 2 Reduced editing activity of high-fidelity Cas9 variants at target sites with a non-G 5’ nucleotide. a Indel frequencies of Cas9-WT and Cas9
variants at 26 endogenous target sites with an HX19 sequence obtained using gX19 sgRNAs in HeLa cells (H: not G [C or T or A]). The sequences and indel
frequencies (%) of the 26 target sites are described in Additional file 1: Table S1. * P< 0.05, ** P< 0.01, **** P< 0.0001. b Distributions of relative indel
frequencies of eCas9-1.1 and Cas9-HF1 normalized to that of Cas9-WT. Means and medians of relative indel frequencies are represented in Additional file 1:
Table S2. Box and whisker plots: center lines show the medians; crosses show the means. c Indel frequencies (measured by targeted deep sequencing) at six
on-target sites with a 5’ C or 5’ T nucleotide obtained using gX19 and gX20 sgRNAs in HeLa cells. PAM sequences are shown in blue. Error bars, s.e.m. of
three biological replicates
Kim et al. Genome Biology  (2017) 18:218 Page 3 of 6
Additional file 1: Table S3a). The ratios of indel frequen-
cies of Cas9 variants in complex with HH-X20 sgRNAs
relative to that of Cas9-WT had medians of 0.9 for eCas9-
1.1 and 0.8 for Cas9-HF1 (Additional file 1: Figure S2,
Table S3b). The two Cas9 variants were poorly active
when combined with HH-gX19 sgRNAs, demonstrating
that the rescue of high-fidelity variants was due to
matched nucleotides at the 5’ end rather than the
ribozyme fusion itself. As expected, Cas9-WT was
equally efficient with HH-X20, HH-X19, and gX19
sgRNAs (P = 0.36, HH-X20 vs HH-X19; P = 0.28, HH-
X20 vs gX19; P = 0.31, HH-X19 vs gX19) (Fig. 3c and
Additional file 1: Table S3a). Editing efficiencies of
eCas9-1.1 and Cas9-HF1 were also increased with
HH-X20 sgRNAs in HEK293T cells (Additional file 1:
Figure S3 and Table S4).
Specificities of Cas9-WT and high-fidelity Cas9 variants in
combination with HH-X20 sgRNAs
Next, we compared the specificities of the two Cas9
variants in complex with HH-X20 sgRNAs by meas-
uring mutation frequencies at known off-target sites
in HeLa cells. The CCR5-01- and EMX1-05-specific
sgRNAs have no known off-target sites and were
a
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Fig. 3 Recovery of editing efficiency of high-fidelity Cas9 variants using HH ribozyme-linked sgRNAs. a A schematic of a self-processing ribozyme
fused sgRNA. The pre-sgRNA contains a HH ribozyme at its 5’-end. The pre-sgRNA undergoes self-cleavage to release a mature sgRNA. The red arrow
indicates the self-cleavage position. b HH ribozyme-fused sgRNAs with a matched 5’ nucleotide (HH-X20) or a mismatched guanosine (HH-gX19) were
tested in combination with Cas9-WT and high-fidelity Cas9 variants at six target sites in HeLa cells. Indel frequencies were measured using targeted
deep sequencing. The PAM is shown in blue. Error bars, s.e.m. of three biological replicates. Statistical significances were calculated by unpaired t-test.
* P < 0.05, ** P < 0.01. c Mean indel frequencies ± s.e.m. at the six target sites in HeLa cells. Statistical significances were calculated by paired t-test. **
P < 0.01, *** P < 0.001
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excluded from this analysis. At most of the off-target
sites that differed from their respective on-target
sites by one to three nucleotides, the two Cas9 vari-
ants showed much lower indel frequencies than
Cas9-WT (Fig. 4). Of note, Cas9-HF1 was able to
discriminate against three off-target sites (one HBB-
03 off-target site and two HBB-04 off-target sites),
each with a single nucleotide mismatch. These re-
sults show that attenuated Cas9 variants retain their
high specificities when combined with HH-X20
sgRNAs. eCas9-1.1 and Cas9-HF1 also showed high
specificities with HH-X20 sgRNAs in HEK293T cells
(Additional file 1: Figure S4).
Discussion and conclusions
In summary, we showed here that newly developed,
high-specificity Cas9 variants, unlike the wild-type
(WT) protein, are often inefficient at target sites with
a mismatch at the 5’ terminus, unequivocally demon-
strating the contribution of the 5’ nucleotide to the
high specificity of CRISPR-Cas9 in human cells for
the first time. Of note, a single 5’-end mismatch be-
tween the sgRNA and target DNA is largely tolerated
by Cas9-WT. The two attenuated Cas9 variants, how-
ever, contain several alanine substitutions to weaken
ionic interactions between the protein and target
DNA, which can make them sensitive to a single
mismatch even at the 5’ terminus. By matching the
first nucleotide of sgRNAs to target DNA via the
self-cleaving activity of a HH-ribozyme fusion, highly
specific genome editing was achieved without sacri-
ficing on-target editing efficiency. As an alternative to
using a HH-ribozyme fusion, sgRNAs with matched
5’ non-G nucleotides could be created via tRNA fu-
sion [14] or chemical synthesis [15] and combined
with the two high-fidelity Cas9 variants. Delivery of
pre-assembled Cas9 variant ribonucleoproteins [16]
rather than Cas9- and sgRNA-encoding plasmids may
further improve genome-wide target specificities of
CRISPR genome editing. Our method expands target-
able sites for high-specificity Cas9 variants, allowing
broad applications in research and medicine.
Methods
Construction of high-fidelity Cas9 variant-encoding plasmids
and the HH-ribozyme-fused sgRNA-encoding plasmid
eCas9-1.1- and Cas9-HF1-encoding plasmids (p3s-
eCas9-1.1, Addgene #104172; p3s-Cas9-HF1, Addgene
#104173) were created via site-directed mutagenesis
of a WT Cas9 construct (p3s-Cas9-HN, Addgene
#104171). HH-ribozyme sgRNA constructs were
cloned via ligation of annealed oligonucleotides that
included a HH-ribozyme sequence and a protospacer
sequence into a plasmid (pRG2, Addgene #104174) in
which sgRNA expression is under the control of the
U6 promoter.
Cell culture and transfection
HeLa cells (ATCC, CCL-2) and HEK 293 T/17 cells
(ATCC, CRL-11268) were maintained in Dulbecco’s
Fig. 4 Specificities of high-fidelity Cas9 variants in combination with HH-X20 sgRNA. The HH-X20 sgRNA expression plasmid was co-transfected
with the plasmid encoding Cas9-WT or a Cas9 variant into HeLa cells. Indel frequencies at on- and off-target sites were measured by targeted
deep sequencing. PAM sequences are shown in blue. Mismatched bases are shown in red. The specificity ratio indicates the fold difference
between the ratio of on-target indel frequencies to off-target indel frequencies obtained using Cas9 variants and that obtained using
Cas9-WT. Error bars, s.e.m. of three biological replicates. Indel frequencies significantly above those of the mock transfected sample are
shown by asterisks (* P < 0.05, ** P < 0.01)
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modified Eagle’s medium (DMEM) supplemented with
100 units/mL penicillin, 100 μg/mL streptomycin,
0.1 mM non-essential amino acids, and 10% fetal bovine
serum (FBS). 0.8 × 105 HeLa cells and 2 × 105 HEK293T/
17 cells were transfected with the Cas9-encoding plas-
mid (0.5 μg) and sgRNA expression plasmid (0.5 μg)
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol.
Western blotting
The Cas9-WT and Cas9 variant proteins expressed in
HeLa cells after transfection were detected using
western blotting. Cas9 and GAPDH were detected
using anti-Cas9 (Abcam, ab191468) and anti-GAPDH
(Santa Cruz Biotechnology, sc-32233) primary anti-
bodies. Goat anti-mouse IgG-HRP antibody (Santa
Cruz Biotechnology, sc-2005) was used for signal de-
tection. ImageQuant LAS4000 (GE healthcare) was
used for digital imaging.
Targeted deep sequencing
The on-target and off-target regions were polymerase
chain reaction (PCR) amplified for NGS library con-
struction. Pooled PCR amplicons were sequenced
using MiniSeq with a TruSeq HT Dual Index system
(Illumina). Indel frequencies were obtained using Cas-
Analyzer [17].
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